Successively, the HERCULES trial extended up to 28 additional days after TPE discontinuation of caplacizumab treatment in patients showing persistent, severe ADAMTS13 deficiency, while optimizing immunosuppressive therapy. Here, ADAMTS13 is linked to hyperinsulinemic hypoglycemia, familial, 4.